BIOCOM InterrelationsESMO 2025Tubulis presents first clinical data on ADC TUB-040Following its US$361 m Series C financing, Tubulis AG presented first Phase I/IIa data on its lead ADC, TUB-040, at ESMO 2025 in Berlin. The study focuseds on patients with platinum-resistant ovarian … more ➔
H Lundbeck A/SNeurology partnershipLundbeck inks licence option deal with Contera PharmaDanish companies H. Lundbeck A/S (Lundbeck) and Contera Pharma A/S have inked a strategic research collaboration aiming at accelerating the development of oligonucleotide-based treatments for medically … more ➔
© Merck KGaAUS Pharma PricesMerck KGaA reduces US prices for IVF drugs by 84%The Merck subsidiary EMD Serono has agreed to price reductions of up to 84% for its in vitro fertilisation products in the United States. To avoid paying pharmaceutical tariffs, the company will distribute … more ➔
Adcytherix SASFinancingADC specialist Adcytherix SAS raises €105m in Series A roundFrench ADC start-up Adcytherix SAS has added €105m Series A funding to a €30m seed financing round closed last year. With the money, the company will start a Phase I study with its lead ADCX-020 … more ➔
Tubulis GmbHADCTubulis secures €308m in record-breaking Series C financing Munich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the … more ➔
BioMed NVMainz BioMed NVBlood test detects pancreatic cancer earlyMainz Biomed NV may have taken a major step in early pancreatic cancer detection. The company reports that its multivariate RNA liquid biopsy test, licensed from Liquid Biosciences Inc. in March, achieved … more ➔
AstraZeneca IncUS marketAstraZeneca agrees to MFN price reductions with US governmentUK-based AstraZeneca plc has become the second of 17 pharmaceutical companies, after Pfizer Inc., to accept U.S. President Donald Trump’s proposal to voluntarily lower drug prices and move production … more ➔
Asebio - Miguel MéndezInterviewBioSpain 2025: “Building European biotech resilience”At BioSpain 2025 European Biotechnology spoke with AseBio CEO Ion Arocena about Spain’s expansion in biotech and its role in a time of geopolitical tensions. more ➔
Novo NordiskNovo NordiskNovo buys again: 5-billion-dollar deal for Akero´s MASHNovo Nordisk is to acquire US-based Akero Therapeutics in a US$5.2 billion deal aimed at reviving growth and entering the MASH-space where others like Roche and GSK have recently expanded their foot … more ➔
AseBioEventBioSpain 2025 starts with new recordsBioSpain 2025 opened in Barcelona, the capital of Catalonia, setting a new record for both visitors and exhibitors. During the inauguration, representatives from government and industry highlighted the … more ➔
BIOCOM Interrelations
H Lundbeck A/S
© Merck KGaA
Adcytherix SAS
Tubulis GmbH
BioMed NV
AstraZeneca Inc
Asebio - Miguel Méndez
Novo Nordisk
AseBio